Method for preparing zalvizepam chiral intermediate
Through the reaction of Compound II with zinc reagent, Negishi coupling and nitrite reaction, combined with palladium catalyst, the preparation efficiency and yield of Zavegipan chiral intermediate I was successfully improved, and the route length and yield in the prior art were solved The problem of low efficiency and low cost industrial production has been achieved.
Patent Information
- Application Number
- CN202310618286.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-30
- Publication Date
- 2024-12-03
AI Technical Summary
In the prior art, the preparation method of Zavejipan chiral intermediate compound I has a long route and low yield. The assembly of chiral amino acids and indazole rings is challenging, and there is a lack of simple operation, short steps, low cost, yield and choice. A highly skilled method.
Compound II is used to react with zinc reagent to prepare compound III, followed by Negishi coupling reaction and nitrite reaction to construct indazole rings, and finally deboced compound I, catalyzed using palladium catalyst and phosphine ligand composition, without the need to separate zinc reagents Solution, isomyl nitrite as reactant.
The preparation of Zavejipan chiral intermediate I with a total yield of 70% was achieved. The steps were short and the yield was high, which reduced the production efficiency and cost, and was suitable for industrial production.
Smart Images

Figure BDA0004254584020000011 
Figure BDA0004254584020000021 
Figure BDA0004254584020000031
Abstract
Description
Technical field:
[0001] The invention belongs to the technical field of organic synthesis, and particularly relates to a method for preparing a chiral intermediate of zavirigopam. Background technology:
[0002] Zavegepant was developed by Bristol-Myers Squibb and launched in the United States on March 9, 2023 under the trade name Zavzpret. It is mainly used to treat acute migraine with or without aura in adults. Its chemical structure is shown below:
[0003]
[0004] In 2011, Bristol-Myers Squibb Company disclosed a method for preparing zavidipam in patent CN102834388B, and the route is shown in Scheme 1. This method uses compounds 1 and 3 as starting materials, and obtains compounds 2 and 4 through iodination and methanesulfonylation / elimination reactions, respectively, and then reacts under the action of palladium acetate to obtain compound 5, and then constructs a chiral center under the catalytic action of [(2R,5R)-Et-DuPhosRh]BF4 to generate compound 6, and finally compound 6 reacts with isopentyl nitrite to construct an indazole ring, and Pd / C hydrogenation removes the CBZ protecting group to complete the preparation of the free compound I', with a total yield of 43%. Subsequently, compound I' undergoes multiple steps of reaction to obtain zavidipam.
[0005]
[0006] It can be seen from Scheme 1 disclosed by the original research company that compound I is a key chiral intermediate for the preparation of zavirigopam.
[0007] In 2012, Bristol-Myers Squibb Company disclosed an improved process for compound I in the document Organic Process Research & Development, 2012, 16 (12), 1953-1966. The route is shown in Scheme 2. The process uses enzyme catalysis to construct the chiral center, using compound 8 as the starting material, and obtaining compound 12 through four steps of reaction. Compound 12 is then converted into compound 13 under the action of D-aminotransferase, and finally compound I is obtained through methyl esterification reaction, with a total yield of less than 40%.
[0008]
[0009] In 2022, patent WO2022172829A1 disclosed a method for preparing compound I by multi-enzyme catalysis, as shown in Scheme 3. In this method, compound 10 undergoes a two-step reaction to obtain an enzymatic substrate compound 15, which is then hydrolyzed under the action of hydantoinase, decarbamylase, hydantoin racemase, etc. to produce compound 13, and finally undergoes a methylation reaction to produce compound I. This reaction involves three enzymes, requires a large amount of cells, and has a low overall yield.
[0010]
[0011] In the prior art, the preparation method of compound I has a long route, low yield, and the assembly of chiral amino acids and indazole rings is very challenging. Therefore, we need to develop a preparation method with simple operation, short steps, low cost, high yield and selectivity. Summary of the invention:
[0012] The purpose of the present invention is to provide a method for preparing a chiral intermediate I of zavirigopam and an intermediate compound thereof, which has simple operation, short route and is easy to industrialize, in view of the deficiencies in the prior art.
[0013] In one aspect, the present invention provides a novel compound, a compound having a structure as shown in Formula V, or a pharmaceutically acceptable salt thereof,
[0014]
[0015] On the other hand, the present invention provides a method for preparing a chiral intermediate of zavirigopam (Compound I), and its technical scheme is shown in Scheme 4.
[0016]
[0017] The invention provides a method for preparing a zavidigpam chiral intermediate I, which specifically comprises the following steps: compound II reacts with a zinc reagent to prepare compound III, compound III undergoes a Negishi coupling reaction with compound IV to obtain compound V, compound V reacts with a nitrous acid compound to construct an indazole ring to generate compound VI, and finally removes Boc to obtain compound I.
[0018] Further, compound II reacts with a zinc reagent to obtain a zinc reagent solution containing intermediate compound III, wherein the zinc reagent is selected from zinc powder.
[0019] Furthermore, the zinc reagent solution of the intermediate compound III does not need to be separated and purified and can be directly used in the next reaction.
[0020] Furthermore, the catalyst required for the Negishi coupling reaction is a palladium catalyst.
[0021] Furthermore, the palladium catalyst and the phosphine ligand exist in the form of a combination, such as a combination of Pd2(dba)3 and P(o-tol)3, a combination of palladium chloride and PPh3, Pd(PPh3)2Cl2, Pd(PPh3)4, etc., more preferably a combination of Pd2(dba)3 and P(o-tol)3.
[0022] Furthermore, the nitrous acid compound is selected from isoamyl nitrite and tert-butyl nitrite, preferably isoamyl nitrite.
[0023] Further, Compound I is in the form of a dihydrochloride salt.
[0024] The beneficial effect of the present invention is that the present invention discloses a new method for preparing a chiral intermediate I of zavirigopam, wherein the method uses compound II as a starting material, and obtains compound I through four-step reactions, with a total yield of 70%. The route has short steps and high yield, greatly reduces production efficiency and production cost, and is easy for industrial production. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] none DETAILED DESCRIPTION
[0026] The technical content of the present invention is further described below in conjunction with specific embodiments, the purpose of which is to provide a better understanding of the content of the present invention, but the protection scope of the present invention is not limited thereto.
[0027] Example 1 Preparation of Compound III
[0028] Under nitrogen protection, zinc powder (90g, 1.38mol, 2.7eq) and N,N-dimethylformamide (280mL, 2v / w) were added to a 2L four-necked bottle in sequence, and nitrogen was replaced three times. TMSCl (5.54g, 0.05mol, 0.1eq) was added and stirred for 30 minutes. Compound II (302g, 0.918mol, 1.8eq) was dissolved in N,N-dimethylformamide (280mL, 2v / w) and slowly added dropwise to the reaction solution at 8-15°C. The reaction was completed for 2 hours, and the obtained reaction solution was directly used for the next step reaction.
[0029] Example 2 Preparation of Compound V
[0030] Compound IV (125 g, 0.51 mol, 1.0 eq), PPh3 (0.94 g, 3.57 mmol, 0.007 eq), Pd(PPh3)2Cl2 (0.32 g, 1.79 mmol, 0.0035 eq), and DMF (250 ml, 2 v / w) were added to a four-necked flask in sequence. The mixture was replaced with nitrogen three times, and the temperature was raised to 88-94 ° C. The solution obtained in Example 1 was added dropwise. The reaction solution gradually turned into a light yellow clear solution, then turned brown, and finally a black solid precipitated. After the addition was completed, stirring was continued for 0.5 hours. The reaction was completed, and DMF was removed by distillation under reduced pressure. 0.2 N sulfuric acid (750 mL, 6 v / w) was added to adjust the pH to 2-3. Dichloromethane was added for extraction, the organic phases were combined, and concentrated under reduced pressure to obtain 138.3 g of compound V with a yield of 84.2% and a purity of 99.5%.
[0031] Example 3 Preparation of Compound V
[0032] Compound IV (125 g, 0.51 mol, 1.0 eq), P(o-tol)3 (1.09 g, 3.57 mmol, 0.007 eq), Pd2(dba)3 (1.64 g, 1.79 mmol, 0.0035 eq), and DMF (250 ml, 2 v / w) were added to a four-necked flask in sequence. The atmosphere was replaced with nitrogen three times, and the temperature was raised to 88-94 ° C. The solution obtained in Example 1 was added dropwise. The reaction solution gradually turned into a light yellow clear solution, then turned brown, and finally a black solid precipitated. After the addition was completed, stirring was continued for 0.5 hours. The reaction was terminated, and DMF was removed by distillation under reduced pressure. 0.2 N sulfuric acid (750 mL, 6 v / w) was added to adjust the pH to 2-3. Dichloromethane was added for extraction, and the organic phases were combined and concentrated under reduced pressure to obtain 147.8 g of compound V with a yield of 90.0% and a purity of 99.8%.
[0033] Example 4 Preparation of Compound VI
[0034] Compound V (32.2 g, 0.1 mol, 1.0 eq), 1.0 L toluene, 65 mL glacial acetic acid, and potassium acetate (58.9 g, 0.6 mol, 6.0 eq) were added to a 2 L four-necked flask in sequence, and then isoamyl nitrite (12.9 g, 0.11 mol, 1.1 eq) was slowly added dropwise at 20-25 ° C. The reaction was stirred for 24 hours until the reaction was completed, saturated sodium carbonate was added dropwise until the pH was 7-8, and dichloromethane was added for extraction. The organic phases were combined and concentrated under reduced pressure, 100 mL of ethyl acetate was added, heated to 65 ° C to dissolve, seed crystals were added, the temperature was lowered to 25 ° C, 200 mL of n-heptane was added, and the filter cake was rinsed with 50 mL of ethyl acetate: n-heptane = 1:3, and the filter cake was vacuum dried at 45 ° C to obtain 28.17 g of compound VI with a purity of 98.2%, a chiral purity of 99.8%, and a yield of 84.5%.
[0035] Example 5 Preparation of Compound I
[0036] Compound VI (25 g, 0.075 mol, 1.0 eq) and 250 mL of 2N HCl methanol solution were added to a 500 mL three-necked flask, the temperature was raised to 25-30 ° C, and stirred for 16 h. After TLC monitoring, the reaction was completed, extracted twice with dichloromethane, filtered, and the filter cake was rinsed with 50 mL of methanol and dried in a vacuum oven at 45 ° C to obtain 21.15 g of compound I with a yield of 92.1%, a purity of 99.0%, and a chiral purity of 99.8%.
Claims
1. A method for preparing a chiral intermediate compound I of zavigipan, characterized in that: The method comprises the following steps: Compound II reacts with a zinc reagent to prepare Compound III, Compound III and Compound IV undergo Negishi coupling reaction to obtain Compound V, Compound V reacts with a nitrous acid compound to generate Compound VI, and finally Boc removal is performed to obtain Compound I.
2. The preparation method according to claim 1, characterized in that The zinc reagent is selected from zinc powder.
3. The preparation method according to claim 1, characterized in that: The nitrite compound is selected from isoamyl nitrite and tert-butyl nitrite.
4. A compound represented by formula V, or a pharmaceutically acceptable salt thereof, 5. The compound V according to claim 4, characterized in that The compound V can be used to prepare the chiral intermediate compound I of zavirigepam.
Citation Information
Patent Citations
Cgrp receptor antagonist
CN102834388B
Method for producing optically active indazolylalanine or indazolyl aldehyde
WO2022172829A1
Cited By
Method of preparation of zavegepant, synthesis intermediates of zavegepant and methods of preparation thereof
WO2025125353A1
Method for preparing zavegepant intermediate and derivative thereof
WO2025209508A1
Process for preparing (r)-2-amino-3-(7-methyl-1h-indazol-5-yl) methyl propanoate, and use thereof as intermediate for the synthesis of zavegepant
WO2025238595A1
